BO
Live price temporarily unavailable.
Price history
Boundless Bio (BOLD) is a Health Care company. Latest news and coverage below.
IPO: March 28, 2024 · $16.00 offering · NASDAQ · View IPO details →
Boundless Bio net income history (FY2023–FY2025)
Net income
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Operating income | −$54.8M | −$73.3M | −$63.6M |
| Net income | −$49.4M | −$65.4M | −$58.2M |
| EPS (diluted) | −$40.65 | −$3.85 | −$2.60 |
| Balance sheet | |||
| Cash and equivalents | $23.7M | $26.6M | $17.9M |
| Total assets | $129.9M | $206.4M | $157.1M |
| Total liabilities | $9.36M | $55.8M | $58.4M |
| Shareholders' equity | −$127.1M | $150.6M | $98.7M |
| Cash flow | |||
| Operating cash flow | −$46.9M | −$60.8M | −$46.7M |
| Capital expenditure | $633.0K | $2.54M | $546.0K |
| Free cash flow | −$47.5M | −$63.4M | −$47.2M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$18.7M | −$18.3M | −$17.3M | −$17.1M | −$15.1M | −$14.0M | −$14.5M | −$24.4M |
| Net income | −$16.5M | −$16.4M | −$15.8M | −$15.7M | −$13.9M | −$12.9M | −$13.6M | −$23.7M |
| EPS (diluted) | −$0.74 | $9.93 | −$0.71 | −$0.70 | −$0.62 | −$0.57 | −$0.60 | −$1.06 |
| Balance sheet | ||||||||
| Cash and equivalents | $40.2M | $26.6M | $15.1M | $14.7M | $15.0M | $17.9M | $17.5M | $20.2M |
| Total assets | $175.1M | $206.4M | $191.2M | $179.5M | $168.7M | $157.1M | $141.0M | $73.7M |
| Total liabilities | $10.0M | $55.8M | $54.6M | $56.8M | $58.6M | $58.4M | $54.6M | $7.77M |
| Shareholders' equity | $165.1M | $150.6M | $136.6M | $122.7M | $110.2M | $98.7M | $86.4M | $66.0M |
| Cash flow | ||||||||
| Operating cash flow | −$13.3M | −$15.6M | −$14.5M | −$11.8M | −$10.2M | −$10.1M | −$15.0M | −$21.0M |
| Capital expenditure | $483.0K | $466.0K | $59.0K | $48.0K | $15.0K | $424.0K | $8.00K | $38.0K |
| Free cash flow | −$13.7M | −$16.0M | −$14.6M | −$11.9M | −$10.2M | −$10.5M | −$15.0M | −$21.0M |
From Boundless Bio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Boundless Bio
- Headquarters
- La Jolla, California From SEC filings, Oct 2026
Recent News (5)
-
Wells Fargo gets a bold upgrade ahead of earnings. Why the stock can play catch-up Wells Fargo received a bold upgrade just over a week before the bank reports earnings next Tuesday.
-
Trump’s recent statements on the economy are even more bonkers than usual | Steven Greenhouse
Our ‘genius’ president is revealing his ignorance of economics, fueling concerns about the threat he poses to the world
Donald Trump recently made a bold claim about his abilities, writing on Truth So…
-
For Kemi, being the Nasty party is not toxic but a badge of honour | John Crace
The Tory leader says the party’s plans to cut people’s benefits are no more than ‘common sense’
It’s a thought. A bold one. Possibly a career-ending one. But a thought nonetheless. When Theresa May to…
-
Abbott Laboratories (NYSE:ABT): Are Investors Getting Over Their Scepticism Over The Company's Bold US$21bn Bet On Exact Sciences? Abbott Laboratories (NYSE:ABT): Are Investors Getting Over Their Scepticism Over The Company's Bold US$21bn Bet On Exact Sciences? Stocks Down Under
-
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International